NASD · Healthcare · Biotechnology · USA
Ionis Pharmaceuticals Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Ionis Pharmaceuticals invents RNA-targeted medicines to treat serious diseases. The company has seven marketed medicines for conditions including familial chylomicronemia syndrome, hereditary angioedema, spinal muscular atrophy, and amyotrophic lateral sclerosis, commercialized through independent launches and partnerships with AstraZeneca and Biogen. Its pipeline includes additional medicines in development.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Ionis Pharmaceuticals Inc stock.
Not valued: We cannot value this company yet.
We do not publish a value for this company: not even its current assets cover what it owes.
17 more funds hold it; the full list is part of the paid plan.
135 more in this industry show a wider margin of safety.
We do not publish a verdict on IONS yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.